Posted in | News | Nanoelectronics | Graphene

UK's Paragraf Acquires Cardea Bio in USA To Extend Graphene Electronics Industry Leadership

Paragraf, the only company in the world to mass produce graphene electronics using transfer-free graphene and standard semiconductor processes, has acquired Cardea Bio, the world’s leading producer of graphene-based biocompatible chips. Cardea Bio is to be renamed Paragraf USA and the San Diego facility, team and operations have already become a valuable part of the Paragraf family.

The creation of Paragraf USA is a significant move towards realising Paragraf’s ambition of a world beyond silicon electronics, where graphene and other 2D materials create faster and more-efficient semiconductor devices and technologies – in short: a new frontier in electronics. This acquisition enables Paragraf to offer a new generation of biosensing devices that will deliver the features and result sensitivity of existing lab-based instruments, with the rapid response and simple ease of use required to enable handheld, real-time, in the field use.

“The world-leading IP and expertise in graphene-electronic-based molecular detection using CRISPR and other bioassay methods from Cardea Bio, combined with Paragraf’s ground-breaking developments in scalable graphene production processes will deliver a strong pipeline of biosensing products aimed at solving major global challenges,” said Simon Thomas, Paragraf CEO and co-founder. “These products will strengthen surveillance of the quality and integrity of our food production processes, markedly improve early detection of disease and monitor the health of our environment. With our existing product lines of current, position and cryogenic sensors – all built on graphene – they will advance Paragraf’s vision of Healthy People, Healthy Cities and Healthy Planet.”

Paragraf Group is now very well positioned for strong growth and will continue to support its current partners and commercial commitments while integration is moving forward, leading to cross-pollination of the two world-class IP portfolios, technology platforms and our people’s great capabilities and ideas. By early summer, we expect the integration to be complete and the product roadmap to be enhanced and go-to-market capabilities sped up to the benefit of our existing and new customers and partners.

“Joining Paragraf allows us to use the world’s only mass-produced, transfer-free monolayer graphene to manufacture the state-of-the art graphene-based biosensors developed by the Cardea team over the last ten years. We are looking forward to unlocking powerful synergistic effects to advance the broad and growing use of graphene biosensors for the benefit of both people and the planet” said Michael Heltzen, EVP of Strategy at Paragraf USA (former CEO and co-founder of Cardea Bio).

Source: https://paragraf.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Paragraf Ltd.. (2023, May 03). UK's Paragraf Acquires Cardea Bio in USA To Extend Graphene Electronics Industry Leadership. AZoNano. Retrieved on May 23, 2024 from https://www.azonano.com/news.aspx?newsID=40217.

  • MLA

    Paragraf Ltd.. "UK's Paragraf Acquires Cardea Bio in USA To Extend Graphene Electronics Industry Leadership". AZoNano. 23 May 2024. <https://www.azonano.com/news.aspx?newsID=40217>.

  • Chicago

    Paragraf Ltd.. "UK's Paragraf Acquires Cardea Bio in USA To Extend Graphene Electronics Industry Leadership". AZoNano. https://www.azonano.com/news.aspx?newsID=40217. (accessed May 23, 2024).

  • Harvard

    Paragraf Ltd.. 2023. UK's Paragraf Acquires Cardea Bio in USA To Extend Graphene Electronics Industry Leadership. AZoNano, viewed 23 May 2024, https://www.azonano.com/news.aspx?newsID=40217.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.